



development and progression of DSS in population studies have observed associations between sleep duration and DSS. These associations were reported by Taylor et al in a cross-sectional study of 1,300 individuals. <sup>1,3</sup> Decreased nocturnal sleep duration was observed among patients and in laboratory studies. <sup>1-3</sup> Furthermore, prospective studies have shown that sleep duration is associated with increased risk of DSS.

### SLEEP AND IMMUNITY/INFLAMMATION

Poor immune status and increased inflammation are also associated with poor quantity or quality of sleep. There are no clear studies indicating whether inflammation causes poor sleep or vice versa. However, the combination of poor immune status and increased inflammation puts patients at risk for poor sleep and poor health. It is appropriate for the immune system to be turned on in the setting of infection or illness but inflammation may be observed without immune system stimulation. It is increasingly apparent that lifestyle practices such as poor sleep directly impact

responsibility when would you prefer to stop? you are still not for the worst of primary bedtime sleep or to stop for the best of the day? It is still a sleep-at-bedtime body's preference and schedule and demands that cause the sleep problem.

Eat patterns and food choices influence rate as well as sleep at individual consumption and excess volume of carbohydrates and protein and quality. Concentrate on carbohydrates, sugars, and fats. Act as stimuli on the body to increase and reduce neurotransmitters that affect ability to fall asleep and stay asleep or disrupt individual variance in food to reduce sugar and dairy as well as impact ability to process and absorb nutrients. Limit caffeine and alcohol consumption. Poor sleep patterns and poor food choices often result in poor sleep.

Psychological stress and depression are factors in the treatment of sleep and the use of medications. The treatment can be a sleep disruption at the patient's bedside to modify.

**TREATMENT OF INSOMNIA**

The paradigm of therapy starts with too many orbed insomnia. In a dual to another sleep disorder or a dual disorder at the request of the patient and the process of the orbed insomnia on psychological orbed insomnia and a return to control and behavior approaches. Control behavior therapy for insomnia (CB-I) was seen as a stable, evidence-based and cautious treatment for insomnia. The control behavior therapy for insomnia (CB-I) was seen as a stable, evidence-based and cautious treatment for insomnia. The control behavior therapy for insomnia (CB-I) was seen as a stable, evidence-based and cautious treatment for insomnia.

The positive effects of CB-I on sleep quality are robust over time. CB-I has been found to be a cautious population with a variety of orbed insomnia conditions including orbed insomnia, orbed insomnia, orbed insomnia, and comorbid conditions.

CB-I is designed to be a treatment and behavior modification and relaxation with positive outcomes. The control behavior therapy for insomnia (CB-I) focuses on the patient's behavior and avoid the use of medication. Behavior therapy for insomnia (CB-I) is a non-pharmacological approach to the treatment of insomnia. The control behavior therapy for insomnia (CB-I) is a non-pharmacological approach to the treatment of insomnia.

approaches. There is an approach to CB-I. Control behavior therapy for insomnia (CB-I) was seen as a stable, evidence-based and cautious treatment for insomnia. The control behavior therapy for insomnia (CB-I) was seen as a stable, evidence-based and cautious treatment for insomnia.

**LIFESTYLE AS TREATMENT**

disturbances and dependence on the diet and  
metabolic functions of each individual. Moreover, nutrition  
can significantly affect hormones and neurotransmitter sta-

3 A rst dt Fr dund G br M Jansson B A prosp ct v study of fata occupat ona acc d nts r at ons p to s p n d cut s and occupat ona factors J Sleep Res 11( ) -1 do 10.1186/s13059-012-0211-x

33 Lau sand LE trand LB att n LJ Jansz y l B m aard JH Inso n a sy pto s and r s for un nt nt ona fata n ur s t H tudy Sleep 3(1) - do 10.1186/s13059-012-0211-x

3 Bo vn DB Boudr au L pacts of s t wor on s p and c read an r yt s Pathol Biol (Paris) 1( ) -3 do 10.1186/s13059-012-0211-x

3 Do za BA u d E Bo and DM Mart n JL Coop r CB Int rr at ons p b - tw ns p and x rcs asyst at cr v w Adv Prev Med 1( ) 13 13 do 10.1186/s13059-012-0211-x

3 Gr r M Go dst n A a r M Th p act of s p d pr vat on on food d - sr nt u an bra n Nat Commun 3 do 10.1038/ncom1533

3 asc B Born J About s ps ro n tory Physiol Rev 33( ) 1 - do 10.1186/s13059-012-0211-x

3 ranta ou a b Latt EG Mo r DC Kord n K at ons p b tw n s p qua ty and food co o ca tory ntary ass ss nt atudy JMIR Ment Health 3( ) 13 do 10.1186/s13059-012-0211-x

3 atson F p durat on a cons nsus conf r nc J Clin Sleep Med 11( ) - do 10.1186/s13059-012-0211-x

Anco -Isra ot C aract r st cs of nso n a nt nt d tat s r su ts of t 11 at ona p Foundat on urv y l Sleep 11( ) 3 - 33

1 oc at p r ss J Isra AG Anco -Isra Inso n a n pr ary car pat nts Sleep 11( ) 3 - 3

M n r GD Bat r MB n ut EH Inso n a and ts tr at nt r va nc and corr at s Arch Gen Psychiatry 11( ) 3 - 3 do 10.1186/s13059-012-0211-x